LQDA vs WST: fair value comparison
Liquidia Corporation and West Pharmaceutical Services, Inc. · Updated 2026-10-19
LQDA's estimate rests on a sector-average multiple, which TickrTrends does not publish as a verdict. Within Healthcare, WST currently ranks higher by quality score. WST carries the stronger quality grade.
| LQDA | WST | |
|---|---|---|
| Verdict | Awaiting full valuation | Fairly valued |
| Last price | $34.35 | $366.00 |
| 12-month range | $22.38–$91.03 | $230.95–$384.02 |
| Rank by discount to fair value | — | #60 of 108 Healthcare |
| Rank by quality score | #47 of 301 Healthcare | #46 of 301 Healthcare |
| Quality grade | B | A |
| Leverage | Moderate | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | — | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: LQDA fair value analysis · WST fair value analysis